EUVIMEDEUVIMED entdecken
Crossref

Lenacapavir to prevent HIV infection: current prices versus estimated costs of production

Andrew Hill iD, Jacob Levi iD, Cassandra Fairhead iD, Victoria Pilkington, Junzheng Wang iD, Madison Johnson, Jevon Layne, David Roberts, Joseph Fortunak

Journal of Antimicrobial Chemotherapy · 04.11.2024 · 79 (11) · 2906-2915

DOI: 10.1093/jac/dkae305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 03.09.2024. Verfasst von Andrew Hill und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Liverpool University, Liverpool, UK. Hauptthemen laut MEDLINE: Anti-HIV Agents, Drug Costs, HIV Infections. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: International Treatment Preparedness Coalition (ITPC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite improvements in treatment and oral pre-exposure prophylaxis (PrEP) access, 1.3 million people acquired HIV in 2022. Six-monthly lenacapavir PrEP could benefit tens of millions of people at high risk of infection. However, prices are currently up to $44 819 per person per year (pppy).

Objectives

We projected minimum lenacapavir pricing based on generic mass production and a Cost-Plus (Cost+) model.

Methods

Current active pharmaceutical ingredient (API) and key starting materials (KSMs) costs were obtained from export databases. The routes of synthesis (ROS) were analysed to project a cost of goods (COGs). Formulation, vials and profit margin costs were included using standardized algorithms and Cost+ pricing. We estimated prices with scale-up to supply 1 million then 10 million treatment-years, comparing this with national list prices.

Results

The lenacapavir API is currently exported from India for $64 480/kg on 1 kg scale. Based on the ROS and KSMs, API COGs of $25 000/kg and $10 000/kg are achievable for a committed demand of 1 million (2 million tonnes/annum of API) and 10 million treatment-years, respectively. Including formulation steps, injectable lenacapavir could be mass produced for approximately $94 pppy for 1 million and $41 for 10 million treatment-years, if voluntary licences are in place and competition between generic suppliers substantially improves. Greater scale-up with improvements in manufacturers’ ROS could reduce prices further. Currently lenacapavir costs $25 395–44 819 pppy.

Conclusions

Lenacapavir could be mass produced for <$100 pppy at launch. Voluntary licensing and multiple suppliers are required to achieve these low prices. This mechanism is already in place for other antiretrovirals. To date, Gilead has not agreed lenacapavir voluntary licences with the Medicines Patent Pool.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsDrug CostsHIV InfectionsCommerceDrug IndustryChemistry, Pharmaceutical

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, Liverpool University, Liverpool, UK.
  • Charité University Hospital, Institute of Tropical Medicine and International Health, Südring 2-3, Berlin, Germany.
  • Postgraduate Medical Education Centre, St George's University Hospitals NHS Foundation Trust, London, UK.
  • Medical Sciences Office, Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK.
  • Chemistry and Pharmaceutical Sciences, Howard University, Washington, D.C., USA.

ORCID-Profile: Andrew Hill, Jacob Levi, Cassandra Fairhead, Junzheng Wang

Förderung

  • International Treatment Preparedness Coalition (ITPC)

Zitieren

APA

Hill, A., Levi, J., Fairhead, C., Pilkington, V., Wang, J., Johnson, M., Layne, J., Roberts, D., & Fortunak, J. (2024). Lenacapavir to prevent HIV infection: current prices versus estimated costs of production. Journal of Antimicrobial Chemotherapy, 79(11), 2906-2915. https://doi.org/10.1093/jac/dkae305

Vancouver

Hill A, Levi J, Fairhead C, Pilkington V, Wang J, Johnson M, et al. Lenacapavir to prevent HIV infection: current prices versus estimated costs of production. Journal of Antimicrobial Chemotherapy. 2024;79(11):2906-2915. doi:10.1093/jac/dkae305

BibTeX
@article{Hill2024,
  author = {Hill, Andrew and Levi, Jacob and Fairhead, Cassandra and Pilkington, Victoria and Wang, Junzheng and Johnson, Madison and Layne, Jevon and Roberts, David and Fortunak, Joseph},
  title = {Lenacapavir to prevent HIV infection: current prices versus estimated costs of production},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {11},
  pages = {2906--2915},
  doi = {10.1093/jac/dkae305}
}
Kostenlos starten →